Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

There are no transmission terms in the subcorpus


Seroprevalence
    displaying 1 - 1 records in total 1
    records per page




    Objective sensory testing methods reveal a higher prevalence SERO of olfactory loss MESHD in COVID-19 positive patients compared to subjective methods: A systematic review and meta-analysis

    Authors: Mackenzie E Hannum; Vicente A Ramirez; Sarah J Lipson; Riley D Herriman; Aurora K Toskala; Cailu Lin; Paule V Joseph; Danielle R Reed

    doi:10.1101/2020.07.04.20145870 Date: 2020-07-06 Source: medRxiv

    Severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), which causes coronavirus disease MESHD 2019 (COVID-19), has currently infected over 6.5 million people worldwide. In response to the pandemic, numerous studies have tried to identify the causes and symptoms of the disease. Emerging evidence supports recently acquired anosmia HP anosmia MESHD (complete loss of smell) and hyposmia (partial HP loss of smell) as symptoms of COVID-19, but studies of olfactory dysfunction MESHD show a wide range of prevalence SERO, from 5% to 98%. We undertook a search of Pubmed/Medline and Google Scholar with the keywords 'COVID-19', 'smell', and/or 'olfaction'. We included any study that quantified olfactory loss as a symptom of COVID%[minus]19. Studies were grouped and compared based on the type of method used to measure smell loss - subjective measures such as self-reported smell loss versus objective measures using rated stimuli - to determine if prevalence SERO rate differed by method type. For each study, 95% confidence intervals (CIs) were calculated from point estimates of olfactory disturbance rates. We identified 34 articles quantifying anosmia HP anosmia MESHD as a symptom of COVID-19, collected from cases identified from January 16 to April 30, 2020. The pooled prevalence SERO estimate of smell loss was 77% when assessed through objective measurements (95% CI of 61.4-89.2%) and 45% with subjective measurements (95% CI of 31.1-58.5%). Objective measures are a more sensitive method to identify smell loss as a result of infection MESHD with SARS-CoV-2. The use of subjective measures, while expedient during the early stages of the pandemic, underestimates the true prevalence SERO of smell loss.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.